一个新的双载荷ADC平台,集成exatecan和triptolide,以提高抗瘤效率和克服抗性
Pengfei Ren1, Menglong Guan1, Jiao Tang1
1Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu, China.
Molecular cancer therapeutics
|October 22, 2025
概括
这项研究引入了一种新型的双有效载荷抗体-药物合物 (ADC),可以克服癌症药物耐药性. 通过结合两个抑制剂,这种ADC显示出显著的抗瘤活性和有利的安全性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 使用拓酶I抑制剂的抗体药物结合物 (ADC) 改善了癌症治疗.
- 耐药性仍然是治疗ADC瘤的一个重大挑战.
- 现有的ADC通常很难有效地克服抵抗机制.
研究的目的:
- 开发一种新的双有效载荷ADC来对抗抗药性瘤.
- 为了提高有效性,创建一个具有双杀死机制的ADC.
- 研究一种在癌症治疗中克服瘤耐药性的策略.
主要方法:
- 埃克萨特干 (EXA) 和三 (TPL) 与同一抗体的共价链接.
- 优化链接器设计,以实现精确的体内药物输送.
- 在体外和体内 (CDX和PDX模型) 评估抗瘤活性.
主要成果:
- 双重有效载荷的ADC证明了精确的药物输送和双重杀伤机制.
- ptolide释放降低了HSP70和P-gp的调节,提高了灵敏度和克服了抵抗力.
- 埃克萨特坎释放进一步抑制了瘤细胞的增殖和生存.
- 在细胞和异种移植模型中观察到显著的抗瘤活性,包括耐药的模型.
- 非GLP的毒性研究表明了有利的安全性.
结论:
- 这种双负载ADC代表了克服瘤耐药性的创新策略.
- 开发的ADC显示了在癌症治疗中临床翻译的巨大潜力.
- 这种方法为耐药癌症患者提供了有前途的治疗结果.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.2K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
